Non-Steroidal Anti-inflammatory Drugs Market Report 2025

The non-steroidal anti-inflammatory drugs market size has grown strongly in recent years. It will grow from $20.68 billion in 2024 to $22.1 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to chronic inflammatory diseases, postoperative pain management, sports injuries, over-the-counter availability, aging population, consumer awareness.

The non-steroidal anti-inflammatory drugs market size is expected to see strong growth in the next few years. It will grow to $28.79 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to emerging pain management therapies, regulatory changes, telehealth utilization, global wellness trends, biosimilar competition, patient preferences, precision medicine approaches. Major trends in the forecast period include over-the-counter (OTC) market dominance, rising preference for cox-2 inhibitors, generics and market competition, integration of digital health technologies, integration of digital health technologies.

The increasing prevalence of chronic pain is projected to drive the growth of the non-steroidal anti-inflammatory drugs (NSAIDs) market. Chronic pain is defined as discomfort that lasts for more than six months, and NSAIDs are commonly used to treat injuries and manage chronic pain. For example, a survey published in July 2022 by the U.S. Pain Foundation, a nonprofit organization based in the U.S., found that 96% of the 2,378 participants reported experiencing increased chronic pain, defined as pain persisting for three months or longer. This included 3% of caregivers and 1% of healthcare professionals surveyed from March to April 2022. Thus, the rising incidence of chronic pain is a key factor driving the growth of the NSAIDs market.

Increasing prevalence of musculoskeletal disorders (MSDs) is set to fuel the growth of the NSAIDs market. MSDs encompass a range of conditions impacting the musculoskeletal system and often requiring pain and inflammation management, for which NSAIDs serve as key therapeutic agents. Factors like an aging demographic, enhanced disease awareness, and greater orthopedic interventions contribute to this surge. A profile by GOV.UK in December 2022 highlighted the upsurge in the prevalence of MSDs among UK individuals aged 16 and above, pointing to a rise from 2021. This escalation underscores the market's trajectory, propelled by the increasing burden of musculoskeletal conditions and the role of NSAIDs in their management.

Product innovation is a significant trend in the non-steroidal anti-inflammatory drugs (NSAIDs) market. Leading companies in this sector are focusing on developing new technological solutions. For example, in February 2024, Hyloris Pharmaceuticals, a Belgium-based firm that specializes in reformulating existing drugs to meet unmet medical needs, launched Maxigesic IV. This intravenous formulation combines paracetamol (acetaminophen) and ibuprofen for the effective management of moderate to severe pain, particularly in postoperative settings. This combination offers enhanced analgesic effects compared to using either drug alone, resulting in more effective pain relief. The intravenous delivery of Maxigesic IV facilitates a rapid onset of action, making it well-suited for acute pain management in clinical environments.

Industry leaders in the NSAIDs market are pursuing new combination therapies to gain competitive advantages. Combination therapies entail the simultaneous use of multiple therapeutic agents or treatments to amplify efficacy or address diverse facets of a condition. For instance, in August 2022, Haleon PLC, a UK-based consumer healthcare company, introduced Advil PLUS Acetaminophen in Canada. This tablet combines ibuprofen and acetaminophen, providing a dual mechanism for pain relief across various pain types. The fusion of these two agents in a single tablet offers an accessible, non-prescription option for pain management, ensuring prolonged relief for up to eight hours. Advil PLUS Acetaminophen stands as an over-the-counter solution available in multiple retail outlets in Canada, showcasing the market's emphasis on effective combination therapies.

In March 2022, Pfizer, a prominent U.S.-based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals for an undisclosed sum. This strategic move enables Pfizer to access Arena Pharmaceuticals' diverse pipeline of developmental-stage therapeutic candidates primarily focused on dermatology, gastroenterology, and cardiology. Notably, this includes etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently undergoing development for various immuno-inflammatory diseases like Crohn's disease, ulcerative colitis, atopic dermatitis, eosinophilic esophagitis, and alopecia. Arena Pharmaceuticals, a U.S.-based company specializing in non-steroidal anti-inflammatory drugs, brings this portfolio of innovative treatments to Pfizer through this acquisition.

Major companies operating in the non-steroidal anti-inflammatory drugs market are Pfizer Inc., Bayer AG, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Assertio Therapeutics Inc., Iroko Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Perrigo Company PLC, Hikma Pharmaceuticals Public Limited Company, Glenmark Pharmaceuticals Limited, Septodont, Aspen Pharmacare Holdings Limited, Sagent Pharmaceuticals Inc., Advanced Pharma Inc., Akorn Operating Company LLC, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Lupin Limited, Cipla Limited, Zydus Cadila Healthcare Limited, Aurobindo Pharma Limited, Sanofi S.A., GlaxoSmithKline PLC, Horizon Therapeutics PLC, Zyla Life sciences, Novartis AG, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company.

North America was the largest region in the non-steroidal anti-inflammatory drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-steroidal anti-inflammatory drugs market during the forecast period. The regions covered in the non-steroidal anti-inflammatory drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-steroidal anti-inflammatory drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Non-steroidal anti-inflammatory drugs (NSAIDs) represent a class of medications designed to alleviate inflammation and reduce fever. They serve as remedies for various ailments including headaches, sprains, painful periods, common colds, flu, arthritis, and other chronic pain conditions. The primary function of NSAIDs is to mitigate inflammation, alleviate pain, and lower elevated body temperatures.

Administration of these drugs primarily occurs through oral ingestion, topical application, and other alternative methods. Topical application is particularly effective in alleviating muscle pains, sprains, and strains, offering relief for painful arthritic conditions. NSAIDs cater to a spectrum of disease indications encompassing arthritis, migraines, ophthalmic disorders, and other related ailments, being accessible through hospital pharmacies, retail outlets, and online pharmacy platforms.

The non-steroidal anti-inflammatory drugs market research report is one of a series of new reports that provides non-steroidal anti-inflammatory drugs market statistics, including non-steroidal anti-inflammatory drugs industry global market size, regional shares, competitors with a non-steroidal anti-inflammatory drugs market share, detailed non-steroidal anti-inflammatory drugs market segments, market trends and opportunities, and any further data you may need to thrive in the non-steroidal anti-inflammatory drugs industry. The non-steroidal anti-inflammatory drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-steroidal anti-inflammatory drugs market consists of sales of high-dose aspirin, indomethacin, mefenamic acid, celecoxib, and other types. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.